Federal reforms will never "fix" the flaws of the pharmaceutical drug system; instead, sponsors need to flex their clout and begin to take full advantage of the power they already possess. (Graphic by Chris Nicholls)
Once again, Congress is attempting to deal legislatively with the lack of transparency in pharmaceutical drug pricing. But most of the focus continues to be on Medicare drug policies, with true reform eluding the commercial/employer-sponsored marketplace.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.